- Home
- SEED vs CLRB Comparison
SEED vs CLRB Comparison
Compare SEED & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- CLRB
- Stock Information
- Founded
- SEED 1997
- CLRB 2002
- Country
- SEED China
- CLRB United States
- Employees
- SEED N/A
- CLRB N/A
- Industry
- SEED Farming/Seeds/Milling
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- CLRB Health Care
- Exchange
- SEED Nasdaq
- CLRB Nasdaq
- Market Cap
- SEED 10.7M
- CLRB 12.6M
- IPO Year
- SEED N/A
- CLRB N/A
- Fundamental
- Price
- SEED $1.43
- CLRB $0.31
- Analyst Decision
- SEED
- CLRB Hold
- Analyst Count
- SEED 0
- CLRB 1
- Target Price
- SEED N/A
- CLRB N/A
- AVG Volume (30 Days)
- SEED 69.6K
- CLRB 617.8K
- Earning Date
- SEED 05-13-2025
- CLRB 05-13-2025
- Dividend Yield
- SEED N/A
- CLRB N/A
- EPS Growth
- SEED N/A
- CLRB N/A
- EPS
- SEED 0.46
- CLRB N/A
- Revenue
- SEED $16,163,803.00
- CLRB N/A
- Revenue This Year
- SEED N/A
- CLRB N/A
- Revenue Next Year
- SEED N/A
- CLRB N/A
- P/E Ratio
- SEED $3.24
- CLRB N/A
- Revenue Growth
- SEED 21.51
- CLRB N/A
- 52 Week Low
- SEED $1.22
- CLRB $0.22
- 52 Week High
- SEED $6.38
- CLRB $3.51
- Technical
- Relative Strength Index (RSI)
- SEED 39.62
- CLRB 53.54
- Support Level
- SEED $1.28
- CLRB $0.23
- Resistance Level
- SEED $1.50
- CLRB $0.32
- Average True Range (ATR)
- SEED 0.16
- CLRB 0.03
- MACD
- SEED -0.01
- CLRB 0.00
- Stochastic Oscillator
- SEED 29.10
- CLRB 92.11
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.